, 24 September, 2019 / 3:00 PM
Pro-life advocates have condemned clinical testing of second trimester chemical abortions on women in a developing country in West Africa.
The tests are being conducted by Gynuity Health Projects, a U.S.-based research company, in Burkina Faso. The trials involve drugs which cause accelerated second trimester chemical abortions.
Since 2017, Gynuity has been conducting a clinical trial of second trimester abortions on pregnant women at 13 to 22 weeks gestation, “to examine the effectiveness and feasibility of a mifepristone-misoprostol medical abortion regimen.” The trial, currently in the “Recruiting” phase, is expected to be finished by the end of 2019.
“That’s such a horrible way to use women in Africa,” Dr. Grazie Pozo Christie, policy advisor for The Catholic Association, told CNA.
“These expecting moms are given dangerous abortion drugs and then literally sent off to pass the body of her aborted child in isolation. How is that not a back-alley abortion?” said Mallory Quigley, vice president of communications for the Susan B. Anthony List.
“It’s unthinkable that the abortion lobby is testing this chemical coat hanger on mothers in the second trimester of their pregnancy in Burkina Faso,” she said.
Gynuity conducts research to influence global reproductive and maternal health policies, and advocates for greater access to chemical abortions around the world. It has conducted clinical trials of second trimester chemical abortions in a number of other countries including Armenia, Nepal, Vietnam, Moldova, Uzbekistan, and Ukraine.
The abortions in Burkina Faso are, according to the trial’s description, to be conducted in accordance with “legal indications.”
According to the Guttmacher Institute, the research arm of Planned Parenthood, abortion is outlawed in Burkina Faso except in cases of rape, incest, severe impairment of the child, or to save the life or protect the health of the mother.
Officials with Gynuity Health Projects did not respond to CNA’s repeated inquiries.
Pro-life criticism of the Africa trials has focused on two objections: that the abortions would be conducted in the second trimester of pregnancy where there is a higher probability of complications, and that they would be conducted in a country with relatively high maternal mortality rates compared to the rest of the world.
Chemical abortions involve a two-step procedure: administration of the drug mifepristone, which stops the mother’s supply of blood to the placenta and cuts off nourishment to the child; followed by misoprostol, which induces contractions and results in the expelling of the child and the placenta from the mother.
The U.S. Food and Drug Administration (FDA) approved a mifepristone-misoprostol regimen in 2000 but has regulations on its use, including a ban on use after 70 days past the first day of the last menstrual cycle of the mother.
The FDA lists mifeprex on its REMS list, or “Risk Evaluation and Mitigation Strategy” that are applied to certain drugs considered to be of special concern.
“Drugs are kept on that list because the way they have to be used is so specific,” Christie said.
Side effects of mifeprex include cramping and bleeding—which, in some cases, requires surgical intervention—as well as nausea, fever, vomiting, headache, diarrhea, and dizziness. Medical supervision is critical because some of the complications of chemical abortions can be lethal, Christie said. “Any fever during this process can be a sign of fatal sepsis,” Christie said.
Previous attempts at studying the viability and effects of second trimester chemical abortions in the United States failed due to lack of enrollment. Researchers concluded that future studies would be better conducted in a different part of the world. According to the practice bulletin of the American College of Obstetricians and Gynecologists, there was a previous trial at University of North Carolina Hospitals was ended because of “slow enrollment.”
“We believe that such a trial will need to be done in Europe or Asia, in settings where labour‐induction abortion is standard,” the report concluded.
Gynuity has conducted second trimester chemical abortion tests in other foreign countries, including Armenia, Nepal, Vietnam, Moldova, Uzbekistan, and Ukraine.
“They clearly are trying to conduct studies in other places that might not be as popular here,” Mary Harned, associate scholar at the Charlotte Lozier Institute, told CNA.
Another controversial aspect of the Gynuity trials in Burkina Faso is the “accelerated” pace of chemical abortions. The FDA-approved regimen can last up to two weeks, yet the trials in Burkina Faso are measuring the rates of a successful second trimester abortion—complete evacuation of the unborn child and the placenta—within 24 hours of the first administration of misoprostol.
The FDA guidelines for the two-drug procedure state that 800mcg of misoprostol should be administered 24-48 hours after 200mg of mifepristone, with a follow-up seven to 14 days afterward with the health care provider.
The trials in Burkina Faso involve administration of 200mg of mifepristone followed by repeat doses of 400mcg of misopristol for every three hours until abortion is achieved.
“They’re super-accelerating and making it a much harder thing for the woman,” Christie told CNA. “They’re basically causing severe uterine contractions and they’re precipitating a labor of a very big child.”
The further along in a woman’s pregnancy, the more complicated the chemical abortion process become, she said. “The complication rate would be huge—will be huge—in these poor women in Africa,” Christie said.
By the second trimester of a woman’s pregnancy, when chemical abortions are not approved by the FDA, “you’re inducing the labor of a perfectly-formed baby,” Christie said. “Here in the United States, we wouldn’t even contemplate it.”
It is unclear from the description of the Gynuity study if the abortions are being conducted in highly-supervised settings in medical clinics, with proximity to a local hospital in case of an emergency.
Burkina Faso has a life expectancy of 60 for males and 61 for females, according to the World Health Organization, and its maternal mortality rate of 371 deaths per 100,000 live births is in the top half of African nations according to a 2018 WHO report, but higher than almost all countries on other continents.
The trials being conducted so late in a woman’s pregnancy in a developing country speak volumes about the abortion movement, pro-lifers told CNA.
“The abortion lobby has been sounding the alarm since the beginning of the push for legal abortion that women’s safety is the issue, that women have to have legal places that they can go to without shame to have these procedures,” Christie said. Now, they are pushing for “chemical abortion outside of safety ranges.”
“It just shows that it was never about women’s safety in the first place,” she said.
Furthermore, the test is being conducted in Africa in a developing country with poor health infrastructure. “That’s pure racism,” she said, “that’s just pure abuse.”
ACI Africa was officially inaugurated on August 17, 2019 as a continental Catholic news agency at the service of the Church in Africa. Headquartered in Kenya’s capital, Nairobi, this media apostolate will strive to facilitate the telling of Africa’s story by providing media coverage of Catholic events on the African continent, giving visibility to the activities of the Church across Africa where statistics show significant growth in numbers and the continent gradually becoming the axis of Catholicism. This is expected to contribute to an awareness of and appreciation for the significant role of the Church in Africa and over time, the realization of a realistic image of Africa that often receives negative media framing.
Father Don Bosco Onyalla
Editor-in-Chief, ACI Africa